pimobendan has been researched along with Canine Diseases in 45 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Excerpt | Relevance | Reference |
---|---|---|
"The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively." | 9.41 | Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021) |
"A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan." | 9.27 | Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. ( Forster, S; Hirakawa, A; King, JN; Otaki, H; Sakakibara, N; Seewald, W; Sonobe, J, 2018) |
"Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated." | 9.22 | Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016) |
"To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD)." | 9.20 | Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015) |
"To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)." | 9.11 | Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005) |
"Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure." | 8.82 | Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004) |
"The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)." | 7.85 | Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017) |
"Pimobendan has gained enormous importance in the treatment of mitral valve disease in dogs." | 6.90 | Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. ( Bach, JP; Iwanuk, N; Nolte, I; Pilgram, A; Raue, J; Rohn, K; Rumstedt, K; Sehn, M; Wall, L, 2019) |
"Pimobendan is an inotropic drug with phosphodiesterase 3 inhibitory and calcium-sensitizing effects." | 5.56 | Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension. ( Kawamoto, S; Miki, S; Morita, T; Nakamura, K; Osuga, T; Sasaoka, K; Takiguchi, M, 2020) |
"The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively." | 5.41 | Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021) |
"Triple therapy (TT) consisting of furosemide, pimobendan, and an angiotensin-converting enzyme inhibitor (ACEI) frequently is recommended for the treatment of congestive heart failure (CHF) attributable to myxomatous mitral valve disease (MMVD)." | 5.34 | Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. ( Bauer, A; Gaugele, J; Glaus, T; Holler, P; Keller, L; Killich, M; Kresken, JG; Küchenhof, H; Simak, J; Wendt, R; Wess, G, 2020) |
"A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan." | 5.27 | Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. ( Forster, S; Hirakawa, A; King, JN; Otaki, H; Sakakibara, N; Seewald, W; Sonobe, J, 2018) |
"Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described." | 5.27 | Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Schummer, C; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2018) |
"Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated." | 5.22 | Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016) |
"To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD)." | 5.20 | Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015) |
"To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)." | 5.11 | Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005) |
"Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure." | 4.82 | Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004) |
"For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day." | 3.88 | Clinical findings and survival time in dogs with advanced heart failure. ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018) |
"The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)." | 3.85 | Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017) |
"This retrospective study reports the survival time [onset of congestive heart failure (CHF) to death from any cause] of 21 dogs with mitral regurgitation (MR) and CHF treated with a combination of furosemide, angiotensin-converting enzyme inhibitor (ACEI, benazepril, or enalapril), pimobendan, spironolactone, and amlodipine." | 3.77 | Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. ( de Madron, E; King, JN; Strehlau, G; White, RV, 2011) |
"Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly." | 3.01 | The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study. ( Bach, JP; Beyerbach, M; Klein, S; Nolte, I; Raue, JF; Rumstedt, K; Sehn, M; Treese, JS; Weiner, F, 2021) |
"Pimobendan has gained enormous importance in the treatment of mitral valve disease in dogs." | 2.90 | Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. ( Bach, JP; Iwanuk, N; Nolte, I; Pilgram, A; Raue, J; Rohn, K; Rumstedt, K; Sehn, M; Wall, L, 2019) |
"Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs." | 2.46 | Current use of pimobendan in canine patients with heart disease. ( Boswood, A, 2010) |
"Pimobendan has been proven to delay the onset of congestive heart failure (CHF) in dogs with mitral regurgitation (MR); however, molecular underlying mechanisms have not been fully elucidated." | 1.91 | Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation. ( Boonpala, P; Ji-Au, W; Kijtawornrat, A; Kumphune, S; Panyasing, Y; Saengklub, N; Srikam, S, 2023) |
" Plasma concentrations of pimobendan and O-demethylpimobendan (ODMP) were measured, and pharmacokinetic parameters were calculated for pimobendan by noncompartmental analysis." | 1.72 | Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus). ( Diao, SM; Gunther-Harrington, CT; Guzman, DS; Hawkins, MG; Knych, HK; Masri, AE; Ozawa, SM, 2022) |
"cardiac death or death for other causes)." | 1.62 | Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols. ( Bagardi, M; Brambilla, PG; Galizzi, A; Locatelli, C; Malchiodi, D; Zanaboni, A, 2021) |
" Angiotensin-converting enzyme inhibitor dosage and RAAS inhibition were greater in stage D, compared to stage C dogs." | 1.56 | Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. ( Adin, D; Atkins, C; Kurtz, K; Papich, MG; Vaden, S, 2020) |
"Pimobendan is a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects." | 1.56 | Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease. ( Bode, EF; Dukes-McEwan, J; Hodgkiss-Geere, HM; Maddox, TW; Neves, J; Sarcinella, F, 2020) |
"Pimobendan is an inotropic drug with phosphodiesterase 3 inhibitory and calcium-sensitizing effects." | 1.56 | Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension. ( Kawamoto, S; Miki, S; Morita, T; Nakamura, K; Osuga, T; Sasaoka, K; Takiguchi, M, 2020) |
"Primary adrenocortical carcinomas developed in the dog met the definition of bilateral incidental adrenal gland masses (IAGMs)." | 1.46 | Clinical and pathological features and outcome of bilateral incidental adrenocortical carcinomas in a dog. ( Hasegawa, A; Itoh, H; Kishimoto, M; Murayama, H; Nabeta, R; Ogawa, M; Ohmori, K; Osada, H; Shibutani, M; Yoshida, T, 2017) |
"In dogs with canine monocytic ehrlichiosis (CME), respiratory signs are uncommon and clinical and radiographic signs of interstitial pneumonia are poorly described." | 1.43 | Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog. ( Broens, EM; Dobak, TP; Toom, ML; Valtolina, C, 2016) |
"Pimobendan has a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting PDEIII." | 1.34 | Effects of pimobendan for mitral valve regurgitation in dogs. ( Hara, A; Kanno, N; Kano, R; Kawasaki, M; Kuse, H; Sasaki, Y, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (20.00) | 29.6817 |
2010's | 22 (48.89) | 24.3611 |
2020's | 14 (31.11) | 2.80 |
Authors | Studies |
---|---|
Klein, S | 1 |
Nolte, I | 3 |
Rumstedt, K | 3 |
Sehn, M | 3 |
Raue, JF | 1 |
Weiner, F | 1 |
Treese, JS | 1 |
Beyerbach, M | 1 |
Bach, JP | 3 |
Bagardi, M | 2 |
Palermo, V | 1 |
Locatelli, C | 2 |
Colombo, FM | 1 |
Pazzagli, L | 1 |
Brambilla, PG | 2 |
Ozawa, SM | 1 |
Guzman, DS | 1 |
Hawkins, MG | 1 |
Diao, SM | 1 |
Masri, AE | 1 |
Gunther-Harrington, CT | 2 |
Knych, HK | 1 |
Kaplan, JL | 2 |
Visser, LC | 2 |
Ontiveros, ES | 1 |
Wittenburg, LA | 1 |
Palm, CA | 1 |
Stern, JA | 1 |
Ellis-Reis, RE | 1 |
Hsue, W | 1 |
Sharpe, AN | 1 |
Boonpala, P | 2 |
Saengklub, N | 2 |
Srikam, S | 1 |
Ji-Au, W | 1 |
Panyasing, Y | 1 |
Kumphune, S | 1 |
Kijtawornrat, A | 2 |
Pirintr, P | 1 |
Hamlin, RL | 1 |
Iwanuk, N | 2 |
Wall, L | 2 |
Raue, J | 2 |
Pilgram, A | 2 |
Rohn, K | 1 |
Adin, D | 1 |
Kurtz, K | 1 |
Atkins, C | 1 |
Papich, MG | 1 |
Vaden, S | 1 |
Sarcinella, F | 1 |
Neves, J | 1 |
Maddox, TW | 1 |
Hodgkiss-Geere, HM | 1 |
Bode, EF | 1 |
Dukes-McEwan, J | 4 |
Pariaut, R | 1 |
Jung, SW | 1 |
Vila, J | 1 |
Newhard, DK | 1 |
Wess, G | 4 |
Kresken, JG | 3 |
Wendt, R | 1 |
Gaugele, J | 1 |
Killich, M | 1 |
Keller, L | 1 |
Simak, J | 1 |
Holler, P | 1 |
Bauer, A | 1 |
Küchenhof, H | 1 |
Glaus, T | 2 |
Morita, T | 1 |
Nakamura, K | 1 |
Osuga, T | 1 |
Kawamoto, S | 1 |
Miki, S | 1 |
Sasaoka, K | 1 |
Takiguchi, M | 1 |
Schober, KE | 1 |
Rush, JE | 2 |
Luis Fuentes, V | 1 |
Summerfield, NJ | 1 |
Wright, K | 1 |
Lehmkuhl, L | 1 |
Sayer, MP | 1 |
Loureiro, J | 1 |
MacGregor, J | 1 |
Mohren, N | 1 |
Zanaboni, A | 1 |
Galizzi, A | 1 |
Malchiodi, D | 1 |
King, JN | 3 |
Hirakawa, A | 2 |
Sonobe, J | 1 |
Otaki, H | 1 |
Sakakibara, N | 1 |
Seewald, W | 1 |
Forster, S | 1 |
Nabeta, R | 1 |
Osada, H | 1 |
Ogawa, M | 1 |
Hasegawa, A | 1 |
Kishimoto, M | 1 |
Murayama, H | 1 |
Yoshida, T | 1 |
Shibutani, M | 1 |
Itoh, H | 1 |
Ohmori, K | 1 |
Boswood, A | 7 |
Gordon, SG | 2 |
Häggström, J | 3 |
Stepien, RL | 3 |
Oyama, MA | 4 |
Keene, BW | 2 |
Bonagura, J | 2 |
MacDonald, KA | 2 |
Patteson, M | 6 |
Smith, S | 6 |
Fox, PR | 2 |
Sanderson, K | 2 |
Woolley, R | 2 |
Szatmári, V | 2 |
Menaut, P | 2 |
Church, WM | 2 |
O'Sullivan, ML | 2 |
Jaudon, JP | 2 |
Rush, J | 2 |
Barrett, KA | 2 |
Rosenthal, SL | 2 |
Saunders, AB | 3 |
Ljungvall, I | 2 |
Deinert, M | 2 |
Bomassi, E | 2 |
Estrada, AH | 2 |
Fernandez Del Palacio, MJ | 2 |
Moise, NS | 3 |
Abbott, JA | 2 |
Fujii, Y | 2 |
Spier, A | 2 |
Luethy, MW | 2 |
Santilli, RA | 2 |
Uechi, M | 3 |
Tidholm, A | 2 |
Schummer, C | 1 |
Watson, P | 2 |
Beaumier, A | 1 |
Yang, VK | 1 |
Freeman, LM | 1 |
Hezzell, MJ | 1 |
Block, CL | 1 |
Laughlin, DS | 1 |
Hillyer, S | 1 |
Hezzell, M | 1 |
Place, E | 1 |
Tjostheim, SS | 1 |
Kellihan, HB | 1 |
Grint, KA | 1 |
Lake-Bakaar, GA | 1 |
Singh, MK | 1 |
Kass, PH | 1 |
Griffiths, LG | 1 |
Toom, ML | 1 |
Dobak, TP | 1 |
Broens, EM | 1 |
Valtolina, C | 1 |
Apple, SM | 1 |
Menciotti, G | 1 |
Braz-Ruivo, L | 1 |
Crosara, S | 1 |
Borgarelli, M | 1 |
Mizuno, M | 1 |
Yamano, S | 1 |
Chimura, S | 1 |
Takusagawa, Y | 1 |
Sawada, T | 1 |
Maetani, S | 1 |
Takahashi, A | 1 |
Mizuno, T | 1 |
Harada, K | 1 |
Shinoda, A | 1 |
Uchida, S | 1 |
Takeuchi, J | 1 |
Mizukoshi, T | 1 |
Endo, M | 1 |
French, A | 3 |
Little, C | 3 |
Swift, S | 3 |
Willis, R | 2 |
Winter, RL | 1 |
Hariu, CD | 1 |
Martin, MW | 1 |
Stafford Johnson, MJ | 1 |
Strehlau, G | 2 |
Bowles, D | 1 |
Fry, D | 1 |
de Madron, E | 1 |
White, RV | 1 |
Caivano, D | 1 |
Birettoni, F | 1 |
Fruganti, A | 1 |
Rishniw, M | 1 |
Knafelz, P | 1 |
Porciello, F | 1 |
McEwan, JD | 1 |
Butson, R | 1 |
Fuentes, VL | 2 |
Smith, PJ | 1 |
French, AT | 1 |
Van Israël, N | 1 |
Smith, SG | 1 |
Swift, ST | 1 |
Lee, AJ | 1 |
Corcoran, BM | 1 |
Summerfield, N | 1 |
Wotton, P | 1 |
Martin, M | 1 |
Johnson, M | 1 |
Culshaw, G | 1 |
Smith, P | 1 |
Ferasin, L | 1 |
Marcora, S | 1 |
Kanno, N | 1 |
Kuse, H | 1 |
Kawasaki, M | 1 |
Hara, A | 1 |
Kano, R | 1 |
Sasaki, Y | 1 |
4 reviews available for pimobendan and Canine Diseases
Article | Year |
---|---|
Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?
Topics: Animals; Arrhythmias, Cardiac; Dog Diseases; Dogs; Heart Diseases; Pyridazines; Vasodilator Agents | 2018 |
Current use of pimobendan in canine patients with heart disease.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Diseases; Ma | 2010 |
Pimobendan and its use in treating canine congestive heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Treatment Outcome | 2011 |
Use of pimobendan in the management of heart failure.
Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Heart Failure; Phosphodiesteras | 2004 |
13 trials available for pimobendan and Canine Diseases
Article | Year |
---|---|
The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
Topics: Animals; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Method; Heart Valve Diseases; Pyridazi | 2021 |
Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
Topics: Animals; Dog Diseases; Dogs; Heart Valve Diseases; Kidney; Mitral Valve; Prospective Studies; Qualit | 2022 |
Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
Topics: Animals; Cardiomegaly; Dog Diseases; Dogs; Echocardiography; Exercise Test; Female; Heart Murmurs; H | 2019 |
Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
Topics: Animals; Dog Diseases; Dogs; Furosemide; Heart Failure; Mitral Valve; Prospective Studies; Pyridazin | 2020 |
Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.
Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; H | 2021 |
Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Dog Diseases; Dogs; Drug Combinatio | 2018 |
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Heart Diseases; Hea | 2018 |
Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs | 2018 |
Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
Topics: Animals; Biomarkers; Dog Diseases; Dogs; Exercise Test; Female; Heart Valve Diseases; Male; Natriure | 2019 |
Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Topics: Animals; Arrhythmias, Cardiac; Breeding; Cardiotonic Agents; Dog Diseases; Dogs; Double-Blind Method | 2015 |
Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Kansas; Lung; Maryland; Mitral Va | 2016 |
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral V | 2016 |
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Electrocardiography; Heart Failure; Mitral Valve; M | 2005 |
28 other studies available for pimobendan and Canine Diseases
Article | Year |
---|---|
Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques.
Topics: Animals; Dog Diseases; Dogs; Furosemide; Humans; Mitral Valve; Pyridazines; Retrospective Studies; S | 2022 |
Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus).
Topics: Administration, Oral; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Half-Life; Male; Pilo | 2022 |
Echocardiographic evaluation of regurgitant fraction in dogs with subclinical myxomatous mitral valve disease: Method comparison, effects of pimobendan, and reproducibility.
Topics: Animals; Dog Diseases; Dogs; Echocardiography; Heart Valve Diseases; Mitral Valve; Reproducibility o | 2023 |
Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation.
Topics: Animals; Dog Diseases; Dogs; Hydrogen Peroxide; Mitochondria; Mitral Valve Insufficiency; Muscle Cel | 2023 |
Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
Topics: Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs; Enalapril; Furosemide; Heart Rate; Mitra | 2023 |
Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dog Diseases; Dogs; Electrolytes; Hear | 2020 |
Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
Topics: Animals; Atrial Function, Left; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Valve Diseases | 2020 |
Resolution of caval syndrome during initial hemodynamic stabilization in dogs with heartworm disease.
Topics: Animals; Cardiotonic Agents; Dirofilariasis; Dog Diseases; Dogs; Female; Heart Diseases; Hemodynamic | 2020 |
Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Hypertension, Pulmonary; Infusion | 2020 |
Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cohort Studies; Death; Dog Diseases; Dogs; Female | 2021 |
Clinical and pathological features and outcome of bilateral incidental adrenocortical carcinomas in a dog.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Amlodipine; Animals; Dog Diseases; Dogs; Female; | 2017 |
Clinical trial results extend drug licence.
Topics: Animals; Clinical Trials as Topic; Dog Diseases; Dogs; Legislation, Drug; Mitral Valve Insufficiency | 2017 |
Clinical findings and survival time in dogs with advanced heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val | 2018 |
Effect of sildenafil and pimobendan on intracardiac heartworm infections in four dogs.
Topics: Animals; Antigens, Helminth; Arsenicals; Dirofilaria; Dirofilariasis; Dog Diseases; Dogs; Female; Fi | 2019 |
Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog.
Topics: Animals; Antiparasitic Agents; Dog Diseases; Dogs; Doxycycline; Ehrlichiosis; Heart Failure; Hyperte | 2016 |
Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral Valve Insuffici | 2017 |
Treatment of congestive heart failure in dogs.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Randomized Controlled T | 2008 |
Canine heart disease: progress and promise.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Dog Diseases; Dogs; Forecasti | 2008 |
ECG of the month. Arrhythmogenic right ventricular cardiomyopathy in a Boxer.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzazepines; Cardiomyopathies; Cardiotoni | 2010 |
Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Breeding; Cardiomyopathy, Dilated; Cardiotonic Ag | 2010 |
Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Clinical Trials as Topic; Dog Diseases; Dogs; Mitral Valv | 2011 |
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Death, Sudden, | 2011 |
Transthoracic echocardiographically-guided interventional cardiac procedures in the dog.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Balloon Valvuloplasty; Benzazepines; Cardiotonic | 2012 |
Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Clinical Trials | 2003 |
Treatment of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Data Interpretation, Statistical; Dog Diseases; Dogs; Heart Failure; Py | 2003 |
Preclinical dilated cardiomyopathy in the dobermann.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Male; Pyridazines; | 2006 |
A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure.
Topics: Animals; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Cardiotonic Agents; Dog Disease | 2007 |
Effects of pimobendan for mitral valve regurgitation in dogs.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiotonic Agents; Catecholamines; | 2007 |